CSPC PHARMA Receives USD15 million Development Milestone Payment for CRB-701

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CSPC PHARMA (01093.HK) +0.315 (+3.945%) Short selling $335.37M; Ratio 31.537% announced that its subsidiary CStone Pharmaceuticals received a USD15 million development milestone payment from Corbus Pharmaceuticals related to CRB-701 (SYS 6002).

To date, CStone Pharmaceuticals has cumulatively received upfront and development milestone payments totaling USD32.5 million from Corbus Pharmaceuticals under the agreement.

The achievement of this milestone marks the steady progress of the relevant R&D work under the agreement as planned. (sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-19 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.